Skip to main content
Quest Diagnostics

Xylazine Detection in Clinical Urine Specimens Ordered for Comprehensive Drug Screening

ADLM 2025

Association for Diagnostics and Laboratory medicine

Chicago, IL, July 27-31 , 2025

Poster presentation: Xylazine Detection in Clinical Urine Specimens Ordered for Comprehensive Drug Screening

Authors: Chen L and Jenkins AJ

Medical Specialty: Prescription drug monitoring, Toxicology

Related content

Test FAQ
Novel Psychoactive Substances (NPS) Panel
Test FAQ
Drug Toxicology Monitoring Oral Fluid Testing
Audio Podcast
Novel Psychoactive Substances (NPS): A Dangerous, Widespread Public Health Issue
On-Demand Webinar
The Growing Crisis of Novel Psychoactive Substances
Audio Podcast
Patients with Substance Use Disorders in Medication-assisted Treatment (MAT)
Test FAQ
Pain Management Antipsychotics With Confirmation Serum and Urine

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.